Products
Olamkicept Biosimilar Fusion Protein (IL-6) for Research
Pre-Made Olamkicept Biosimilar, Fusion Protein targeting IL6 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Olamkicept, also known as soluble gp13Fc or sgp13Fc (other designations are FE 99931, FE31, TJ31) is an immunosuppressive drug candidate, which selectively blocks activities of the cytokine Interleukin-6, which are mediated by the soluble Interleukin-6.[1] Interleukin-6 is a cytokine, which plays a dominant role in the regulation of the immune response and also in autoimmunity. Furthermore, Interleukin-6 has been demonstrated to be involved in the regulation of metabolism and body weight.[2] Interleukin-6 also has many activities on neural cells.[3] The biochemical principle was invented by the German biochemist Stefan Rose-John and it was further developed into a biotech compound by the Conaris Research Institute AG, which gave an exclusive world-wide license to the Swiss-based biopharmaceutical company Ferring Pharmaceuticals.[4] In December 216, Ferring and the biotech company I-MAB signed a licensing agreement granting I-MAB exclusive rights in Asia to Olamkicept for the treatment of autoimmune disease.[5]
The olamkicept is an extracellular portion of gp130 fused to the constant portion of a human IgG1 antibody. Olamkicept is an immunosuppressive drug candidate, which selectively blocks activities of the cytokine Interleukin-6, which are mediated by the soluble Interleukin-6.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-932-1mg | 1mg | 3090 |
| GMP-Bios-INN-932-10mg | 10mg | |
| GMP-Bios-INN-932-100mg | 100mg | |
| GMP-Bios-INN-932-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Olamkicept Biosimilar, Fusion Protein targeting IL6 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 |
| INN Name | Olamkicept |
| Target | IL6 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [IL6ST (interleukin 6 signal transducer, "interleukin 6 signal transducer (gp130, oncostatin M receptor)", CD130, GP130, "gp130, oncostatin M receptor", "Interleukin-6 receptor subunit beta") 23-617]2 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [IL6ST (interleukin 6 signal transducer, "interleukin 6 signal transducer (gp130, oncostatin M receptor)", CD130, GP130, "gp130, oncostatin M receptor", "Interleukin-6 receptor subunit beta") 23-617]2 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Ferring Pharmaceuticals (Saint-Prex Switzerland) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - IL6
1. Protein Interleukin-6
2. Gene IL6
3. Organism Homo sapiens (Human)
Function
Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).
IL6 is a potent inducer of the acute phase response. Rapid production of IL6 contributes to host defense during infection and tissue injury, but excessive IL6 synthesis is involved in disease pathology. In the innate immune response, is synthesized by myeloid cells, such as macrophages and dendritic cells, upon recognition of pathogens through toll-like receptors (TLRs) at the site of infection or tissue injury (Probable). In the adaptive immune response, is required for the differentiation of B cells into immunoglobulin-secreting cells. Plays a major role in the differentiation of CD4+ T cell subsets. Essential factor for the development of T follicular helper (Tfh) cells that are required for the induction of germinal-center formation. Required to drive naive CD4+ T cells to the Th17 lineage. Also required for proliferation of myeloma cells and the survival of plasmablast cells (By similarity).
Acts as an essential factor in bone homeostasis and on vessels directly or indirectly by induction of VEGF, resulting in increased angiogenesis activity and vascular permeability (PubMed:17075861, PubMed:12794819).
Induces, through 'trans-signaling' and synergistically with IL1B and TNF, the production of VEGF (PubMed:12794819).
Involved in metabolic controls, is discharged into the bloodstream after muscle contraction increasing lipolysis and improving insulin resistance (PubMed:20823453).
'Trans-signaling' in central nervous system also regulates energy and glucose homeostasis (By similarity).
Mediates, through GLP-1, crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand (By similarity).
Also acts as a myokine (Probable). Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity).
Also has a pivotal role in iron metabolism by regulating HAMP/hepcidin expression upon inflammation or bacterial infection (PubMed:15124018).
Through activation of IL6ST-YAP-NOTCH pathway, induces inflammation-induced epithelial regeneration (By similarity).
